Roivant (ROIV) Director James C. Momtazee Receives Awards

What Happened
James C. Momtazee, a director of Roivant Sciences Ltd. (ROIV), received two awards on 2026-09-16 reported on Form 4 filed 2026-09-18. The filing shows:

• 5,054 restricted stock units (RSUs) granted (reported at $0.00 per share; total $0).
• 10,531 stock options (derivative security) granted (reported at $0.00; total $0).
  Both awards are coded as "A" (award/grant) and are compensation-related—not purchases or sales.

Key Details

• Transaction date: 2026-09-16; Form 4 filed: 2026-09-18 (appears timely).
• Grant price reported: $0.00 for both RSUs and options (typical for compensation awards at grant).
• Vesting/exercisability: both awards vest/become exercisable 100% on 2027-09-16, subject to continued service as a director (Footnotes F1 & F2).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Transaction code: A = Award/Grant. No indication of 10b5-1, tax withholding, cashless exercise, or late filing in the supplied details.

Context
Awards to non-employee directors are a routine part of director compensation and do not represent an open-market purchase (which some investors view as a stronger bullish signal). The option grant is a derivative award; it does not reflect an exercise or immediate sale. The awards vest fully one year after grant, contingent on continued service.